DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Harbeck N, Huang CS, Hurvitz S. et al.
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment
(LUX-Breast 1): an open-label, randomised, phase 3 trial.
Lancet Oncol 2016;
17: 357-366
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.